Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
INZY Inozyme Pharma Inc
- Stocks
- Healthcare
- NASDAQ: INZY
Price (delayed)
$3.95
Market cap
$255.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.69
Enterprise value
$275.82M
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in
Highlights
The quick ratio has plunged by 85% YoY and by 41% from the previous quarter
The equity has dropped by 73% year-on-year and by 45% since the previous quarter
Key stats
What are the main financial stats of INZY
Market
Valuations
Earnings
Shares outstanding
64.56M
Market cap
$255.02M
Enterprise value
$275.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$107.38M
Net income
-$106.72M
EBIT
-$101.08M
EBITDA
-$99.76M
Free cash flow
-$96.55M
Per share
Balance sheet
Liquidity
EPS
-$1.69
EPS diluted
-$1.69
Free cash flow per share
-$1.5
Book value per share
$0.49
Revenue per share
$0
TBVPS
$1.48
Total assets
$95.16M
Total liabilities
$63.37M
Debt
$46.95M
Equity
$31.8M
Working capital
$50.86M
Debt to equity
1.48
Current ratio
2.19
Quick ratio
1.99
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.5%
Return on equity
-160%
Return on invested capital
-79.9%
Return on capital employed
-193%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INZY stock price
How has the Inozyme Pharma stock price performed over time
Intraday
178.17%
1 week
243.48%
1 month
310.69%
1 year
-16.49%
YTD
42.6%
QTD
334.07%
Financial performance
How have Inozyme Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$107.38M
Net income
-$106.72M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 38% YoY and by 4.6% QoQ
INZY's operating income is down by 32% year-on-year and by 3.2% since the previous quarter
Price vs fundamentals
How does INZY's price correlate with its fundamentals
Growth
What is Inozyme Pharma's growth rate over time
Valuation
What is Inozyme Pharma stock price valuation
P/E
N/A
P/B
7.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INZY's EPS is down by 23% year-on-year and by 4.3% since the previous quarter
The equity has dropped by 73% year-on-year and by 45% since the previous quarter
The price to book (P/B) is 25% higher than the 5-year quarterly average of 2.3 but 4.3% lower than the last 4 quarters average of 3.0
Efficiency
How efficient is Inozyme Pharma business performance
INZY's ROE has dropped by 173% year-on-year and by 39% since the previous quarter
The company's return on assets has shrunk by 96% YoY and by 21% QoQ
The company's return on invested capital has shrunk by 92% YoY and by 29% QoQ
Dividends
What is INZY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INZY.
Financial health
How did Inozyme Pharma financials performed over time
Inozyme Pharma's total assets is 50% higher than its total liabilities
The quick ratio has plunged by 85% YoY and by 41% from the previous quarter
Inozyme Pharma's current ratio has plunged by 84% YoY and by 38% from the previous quarter
The company's debt is 48% higher than its equity
The debt to equity has soared by 83% from the previous quarter
The equity has dropped by 73% year-on-year and by 45% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.